The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial introduction generated massive profits, the expiration of its exclusive rights opened the door to generic alternatives, dramatically reducing sales. This poses a unique risk for pharmaceutical companies relying on comparable blockbuste

The story of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, yielding billions in sales , its intellectual property lapse created a wave of knock-off medications, significantly eroding its position . While certain businesses may try to capitalize on male sexual dysfunction, the present